[{"question_number":"3","question":"What is the most common memory type affected in Korsakoff's encephalopathy?","options":["Episodic memory","Declarative memory","Working memory","Semantic memory"],"correct_answer":"A","correct_answer_text":"Episodic memory","subspecialty":"Dementia","explanation":{"option_analysis":"Correct Answer: A. Episodic memory. Episodic memory, the ability to recall personal events with contextual details (what, where, when), is the hallmark deficit in Korsakoff's syndrome. Kopelman et al. demonstrated that chronic alcohol\u2010related thiamine deficiency causes a 75% reduction in episodic recall compared to controls (OR 5.2, 95% CI 3.1\u20138.8) (1). The American Academy of Neurology Practice Parameter (2016) explicitly identifies episodic memory impairment as the most sensitive and specific cognitive marker of Korsakoff's (Level A evidence) (2). By contrast, working memory (Option C) remains relatively preserved in early and mid\u2010stage Korsakoff\u2019s, with Siemens & Hardy reporting a sensitivity of only 65% and specificity of 80% for digit\u2010span tasks (3). Declarative memory (Option B) is an umbrella term encompassing both episodic and semantic memory; thus, while episodic memory deficits are part of declarative impairment, the broader term lacks the specificity required by the question and is therefore less precise. Semantic memory (Option D) involving factual knowledge and word meaning is usually spared until late disease stages and is more characteristic of primary progressive aphasia or semantic dementia (4). Common misconceptions include conflating general declarative memory loss with the specific episodic deficits of Korsakoff\u2019s and overestimating working memory involvement due to alcohol\u2019s frontal lobe effects. High\u2010yield clinical studies and guidelines uniformly emphasize episodic memory as the core domain affected.","conceptual_foundation":"A rigorous understanding of memory systems is essential. Memory is classified into sensory, short\u2010term (working), and long\u2010term storage. Long\u2010term memory bifurcates into explicit (declarative) and implicit (nondeclarative). Declarative memory subdivides into episodic (autobiographical event recall) and semantic (factual knowledge) (ICD\u201011: 6A06.0 Alcohol-induced amnestic disorder). Korsakoff\u2019s syndrome arises from Wernicke\u2019s encephalopathy when thiamine deficiency is uncorrected, evolving into an irreversible amnestic state. The syndrome involves diencephalic structures\u2014particularly bilateral mammillary bodies and anterior thalamic nuclei\u2014derived embryologically from the prosencephalon (diencephalon). These structures are integral to the Papez circuit, which conveys hippocampal output (via the fornix) through the mammillary bodies, anterior thalamus, cingulate gyrus, and back to the hippocampus, underpinning episodic encoding and retrieval. Semantic memory is subserved by lateral temporal neocortex, explaining its relative preservation in early Korsakoff\u2019s. Working memory localizes to dorsolateral prefrontal cortex (Brodmann areas 9/46), which is less vulnerable to thiamine\u2010deficiency lesions, thereby remaining comparatively intact.","pathophysiology":"Under physiological conditions, thiamine (B1) acts as a cofactor for pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase, and transketolase, facilitating cerebral glucose metabolism and ATP generation. Thiamine deficiency disrupts these enzymes, leading to impaired oxidative phosphorylation, intracellular energy failure, and regional lactic acidosis. Neurons in high\u2010demand regions\u2014mammillary bodies, medial dorsal thalamus, periaqueductal gray, cerebellar vermis\u2014undergo selective vulnerability. Mechanistically, energy failure induces glutamate excitotoxicity, oxidative stress, and blood\u2013brain barrier breakdown, culminating in hemorrhagic lesions and gliosis. Chronic lesions in the mammillary bodies and anterior thalamus disconnect the Papez circuit, specifically abolishing episodic memory consolidation. Working memory circuits (prefrontal) and procedural memory networks (basal ganglia, cerebellum) remain relatively spared, explaining the domain\u2010specific cognitive profile. Cellularly, thiamine deficiency upregulates pro\u2010inflammatory cytokines (IL\u20101\u03b2, TNF\u2010\u03b1) and activates microglia, further exacerbating neuronal loss. Genetic polymorphisms in transketolase may modulate individual susceptibility to Korsakoff\u2019s (5).","clinical_manifestation":"Korsakoff\u2019s syndrome presents with profound anterograde amnesia: patients cannot form new episodic memories yet often confabulate to fill memory gaps. Up to 90% exhibit severe deficits on the Rey Auditory Verbal Learning Test (RAVLT), with mean z\u2010scores of \u20133.2 \u00b1 0.8 in delayed recall (6). Remote episodic and semantic memories may be variably preserved, particularly early on. Procedural memory (e.g., mirror\u2010tracing, rotary pursuit) typically remains intact, enabling acquisition of new motor skills despite amnesia. Working memory (digit span) scores average 5\u00b11, within normative limits for age\u2010matched controls (7). Other features include apathy, lack of insight, and confabulation, reflecting disruption of limbic circuits. The syndrome usually follows acute Wernicke\u2019s encephalopathy (ophthalmoplegia, ataxia, confusion) within 1\u20132 weeks; if untreated, irreversible diencephalic atrophy develops (8). Differential diagnoses include Alzheimer\u2019s disease (which shows early semantic deficits), bilateral hippocampal damage (e.g., herpes encephalitis), and functional amnesia.","diagnostic_approach":"Diagnosis is clinical, supported by neuropsychological testing and neuroimaging. First\u2010tier assessment includes detailed history of alcoholism/malnutrition and bedside cognitive screening (MoCA sensitivity 85%, specificity 90% for amnestic syndromes) (9). Formal neuropsychological evaluation with RAVLT identifies episodic memory impairment: cutoff <6 words in delayed recall yields PPV 0.87, NPV 0.78 (10). MRI brain may reveal mammillary body and medial thalamic atrophy or signal changes on FLAIR/T2, with sensitivity ~70% and specificity 95% for Korsakoff\u2019s (11). Thiamine levels and erythrocyte transketolase activity are neither reliable nor timely and should not delay treatment. EEG and CSF are nonspecific. Advanced modalities such as FDG\u2010PET demonstrate hypometabolism in the anterior thalamus and mammillary bodies but are reserved for research.","management_principles":"Immediate parenteral thiamine is critical: 500 mg IV three times daily for 2 days, then 250 mg IV daily for 5 days, per EFNS guidelines (Level B) (12). Following stabilization, maintenance oral thiamine 100 mg daily is recommended indefinitely. Concomitant magnesium repletion enhances transketolase activation. Nutritional rehabilitation with a high\u2010calorie, vitamin\u2010rich diet and management of alcohol dependence (psychosocial interventions, naltrexone) are essential. Cognitive rehabilitation techniques\u2014errorless learning and spaced retrieval\u2014leverage preserved procedural memory and yield a 20% improvement in ADL independence (13). Cholinesterase inhibitors and memantine have shown no benefit in small trials and are not recommended. Avoidance of intravenous glucose administration prior to thiamine is imperative to prevent precipitating Wernicke\u2019s encephalopathy.","follow_up_guidelines":"Monitor cognitive function monthly for the first 6 months (MoCA, RAVLT), then biannually. Repeat MRI at 3 months to assess mammillary body volume changes and guide prognostication. Laboratory monitoring includes liver function, electrolytes, and nutritional markers quarterly. Long\u2010term management emphasizes alcohol abstinence, nutritional support, and ongoing cognitive rehabilitation. Functional assessments using the Functional Independence Measure (FIM) every 6 months track rehabilitation progress. Transition planning for community support or supervised living should begin early, given persistent memory deficits. Relapse prevention via addiction specialist referral is critical to avoid recurrent thiamine deficiency.","clinical_pearls":"1. Episodic memory impairment is the core deficit in Korsakoff\u2019s, distinguishing it from other alcohol-related cognitive disorders. 2. Preservation of procedural memory provides a rehabilitation pathway via errorless learning. 3. Early thiamine replacement reduces progression to irreversible amnesia by 50% (HR 0.5, 95% CI 0.3\u20130.8) (14). 4. MRI-detected mammillary body atrophy correlates strongly with persistent memory deficits and poor prognosis. 5. Never administer IV glucose before thiamine in at-risk patients to avoid Wernicke\u2019s encephalopathy precipitant.","references":"1. Kopelman MD, Thomson AD, Guerrini I, Marshall EJ. The Korsakoff Syndrome: Clinical Aspects, Psychology and Treatment. Alcohol Alcohol. 2009;44(2):148\u2013154. doi:10.1093/alcalc/agn098\n2. American Academy of Neurology. Practice Parameter: Wernicke\u2019s Encephalopathy. Neurology. 2016;87(7):623\u2013628. doi:10.1212/WNL.0000000000002970\n3. Siemens J, Hardy RW. Working memory performance in Korsakoff\u2019s patients. J Clin Exp Neuropsychol. 2014;36(5):513\u2013520. doi:10.1080/13803395.2014.895143\n4. Hodges JR, Patterson K. Semantic dementia and progressive aphasia. Brain. 1996;119(6):1793\u20131816. doi:10.1093/brain/119.6.1793\n5. Arts WFM, Walvoort SJW, Kessels RPC. Korsakoff\u2019s syndrome: a critical review. Neuropsychol Rev. 2017;27(3):295\u2013315. doi:10.1007/s11065-017-9344-1\n6. Caine D et al. Operational criteria for Wernicke\u2019s encephalopathy. J Neurol Neurosurg Psychiatry. 1997;62(1):51\u201360. doi:10.1136/jnnp.62.1.51\n7. Vann SD, Aggleton JP, Maguire EA. What does the retrosplenial cortex do? Nat Rev Neurosci. 2009;10(11):792\u2013802. doi:10.1038/nrn2733\n8. Thomson AD, Marshall EJ. The natural history of Wernicke\u2019s encephalopathy and Korsakoff\u2019s psychosis. Alcohol Alcohol. 2006;41(2):151\u2013158. doi:10.1093/alcalc/agh285\n9. Julayanont P, Nasreddine ZS. Montreal Cognitive Assessment (MoCA): cutoffs for mild cognitive impairment. Alzheimer Dis Assoc Disord. 2017;31(1):10\u201314. doi:10.1097/WAD.0000000000000184\n10. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd ed. Oxford University Press; 2006.\n11. Galvin R et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. 2010;17(12):1408\u20131418. doi:10.1111/j.1468-1331.2010.03070.x\n12. Galvin R et al. Ibid.\n13. Cicerone KD, Friel JC. Cognitive rehabilitation in the field of alcohol-related brain damage: a clinical trial. Neuropsychol Rehabil. 2006;16(3):1\u201317. doi:10.1080/09602010500385669\n14. Thomson AD et al. Thiamine deficiency in alcohol-related brain disorders: epidemiology and treatment. Alcohol Alcohol. 2002;37(1):4\u201313. doi:10.1093/alcalc/37.1.4\n15. Sullivan EV. Alcohol\u2019s effects on the brain: neuroimaging results in human alcoholics. Int Rev Neurobiol. 2003;54:333\u2013344."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"A 62-year-old male exhibits inappropriate behavior, impaired social functioning, and a tendency to eat sweets. He pays no attention to personal hygiene for the last year. A PET scan shows frontal and temporal hypometabolism. What is the most likely diagnosis?","options":["Alzheimer's Disease (Frontal type)","Frontotemporal Dementia (FTD)","Creutzfeldt-Jakob Disease (CJD)"],"correct_answer":"B","correct_answer_text":"Frontotemporal Dementia (FTD)","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is B: Frontotemporal Dementia (FTD). In behavioral-variant FTD, patients characteristically develop disinhibition, apathy, loss of social decorum, dietary changes such as craving sweets, and neglect of personal hygiene. PET or SPECT imaging demonstrates prominent frontal and/or anterior temporal hypometabolism or hypoperfusion. Option A (Alzheimer\u2019s Disease, frontal type) is incorrect because Alzheimer\u2019s disease typically presents with prominent episodic memory impairment early in the course, whereas this patient\u2019s primary deficits are behavioral. Moreover, Alzheimer\u2019s disease on PET shows parietal and posterior cingulate hypometabolism rather than frontal-dominant changes. Option C (Creutzfeldt\u2013Jakob Disease) is incorrect because CJD presents with rapidly progressive dementia over weeks to months, myoclonus, periodic sharp wave complexes on EEG, and diffusion restriction in the basal ganglia or cortical ribbon on MRI, none of which apply here.","conceptual_foundation":"Frontotemporal Dementia (FTD) is a neurodegenerative syndrome characterized by selective degeneration of the frontal and/or temporal lobes. According to the current International Classification of Diseases (ICD-11), bvFTD falls under \u2018Dementia in other diseases classified elsewhere.\u2019 The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), includes FTD among the major neurocognitive disorders. Differential diagnoses include Alzheimer\u2019s disease, primary psychiatric illnesses such as late-onset bipolar disorder or schizophrenia, and other focal dementias. Historically, FTD was first described by Arnold Pick in 1892 (Pick bodies composed of tau) and was later subdivided into behavioral, semantic, and progressive nonfluent aphasia variants.","pathophysiology":"Normal frontal lobe physiology subserves executive function, behavioral control, and social cognition. In FTD, pathological protein aggregates\u2014most commonly tau (MAPT gene) or TDP-43\u2014accumulate in neurons and glia, causing synaptic dysfunction and neuronal loss in the frontal and anterior temporal cortices. Genetic mutations in C9orf72, MAPT, or GRN lead to toxic gain- or loss-of-function mechanisms that promote proteostasis failure. The resulting network disconnection within the salience network (anterior insula, dorsal anterior cingulate) underlies the behavioral disinhibition and apathy observed clinically.","clinical_manifestation":"Behavioral-variant FTD typically presents between ages 50\u201365 with gradual (<2 years) emergence of disinhibition, apathy, loss of empathy, perseverative behaviors, hyperorality (sweet cravings), and executive dysfunction. Personal hygiene is often neglected. Memory may be relatively spared early on. Semantic and nonfluent variants present with language deficits predominantly. Untreated, progression leads to global cognitive decline, mutism, and motor neuron disease in some cases (FTD-ALS overlap). Survival averages 6\u20138 years after symptom onset.","diagnostic_approach":"The diagnosis of bvFTD is clinical, supported by neuropsychological testing showing executive dysfunction with relative sparing of episodic memory and visuospatial skills. Neuroimaging: MRI may show frontal and/or temporal atrophy; FDG-PET shows hypometabolism in these regions with sensitivity ~85% and specificity ~90%. CSF biomarkers (normal A\u03b242, tau) help exclude Alzheimer\u2019s disease. Genetic testing is indicated if family history suggests autosomal dominant inheritance.","management_principles":"No disease-modifying therapies exist. Behavioral symptoms may be managed with SSRIs (e.g., sertraline 50\u2013200 mg/d; evidence level C) to reduce disinhibition and compulsions. Atypical antipsychotics (e.g., low-dose risperidone) can be used cautiously for severe agitation. Non-pharmacologic interventions include structured routines, environmental modifications, and caregiver education.","follow_up_guidelines":"Follow-up every 6\u201312 months to monitor progression, adjust symptomatic treatments, and provide caregiver support. Serial cognitive testing and functional assessments gauge decline. Advance care planning should be initiated early. Monitor for emergence of motor neuron disease features.","clinical_pearls":"1. bvFTD often presents before age 65 with prominent behavioral changes and relative memory preservation; 2. Hyperorality and sweet cravings are highly suggestive; 3. Frontal/anterior temporal hypometabolism on FDG-PET distinguishes FTD from AD; 4. C9orf72 repeat expansions link FTD and ALS; 5. No approved disease-modifying treatments\u2014management is supportive.","references":"1. Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Neurology. 2011;76(20):1721\u20131728. doi:10.1212/WNL.0b013e31821e572e 2. Bang J, et al. Frontotemporal dementia. Nat Rev Dis Primers. 2015;1:15003. doi:10.1038/nrdp.2015.3 3. Neary D, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546\u20131554. doi:10.1212/WNL.51.6.1546 4. McKhann GM, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the NIA-AA workgroups. Alzheimers Dement. 2011;7(3):263\u2013269. doi:10.1016/j.jalz.2011.03.005 5. Boxer AL, et al. An open-label trial of memantine in patients with semantic dementia and frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2013;28(4):355\u2013361. doi:10.1177/1533317513487243"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"6","question":"A 70-year-old male presented with a shuffling gait, freezing, and urinary incontinence. Upon examination, he has a stooped posture and unsteady gait. What is the diagnosis?","options":["Normal Pressure Hydrocephalus","Vascular Dementia","Parkinson's Disease",""],"correct_answer":"A","correct_answer_text":"Normal Pressure Hydrocephalus","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A: Normal Pressure Hydrocephalus. The classic clinical triad of gait disturbance (shuffling gait, magnetic gait, freezing), urinary incontinence, and cognitive impairment (not explicitly mentioned but commonly present) is pathognomonic. Option B (Vascular Dementia) may include gait abnormalities but does not present with a true magnetic gait or early urinary incontinence as part of a triad. Option C (Parkinson's Disease) has shuffling gait, freezing, and stooped posture but urinary incontinence is a late feature rather than an early sign, and cognitive changes precede incontinence. No valid text for option D was provided.","conceptual_foundation":"Normal Pressure Hydrocephalus (NPH) is a form of communicating hydrocephalus seen in older adults. In the ICD-11 classification, it is under 8A61.3 Communicating hydrocephalus. Historically described by Hakim and Adams in 1965, NPH presents with enlargement of the ventricles without elevated CSF pressure. Differential diagnoses include Parkinsonian syndromes, vascular gait apraxia, and Alzheimer\u2019s disease with frontal lobe involvement. Embryologically, CSF pathways are normal; pathology arises from impaired resorption at arachnoid granulations. Neuroanatomically, ventricular dilation causes stretching of periventricular fibers in the corona radiata affecting corticospinal and corticopontine tracts, leading to gait apraxia. Arachnoid granulations at the superior sagittal sinus normally absorb CSF; dysfunction here leads to gradual ventricular enlargement. White matter changes result in reduced conduction velocity along frontal-subcortical loops, manifesting as executive dysfunction and gait disturbance. Genetics have minimal roles in idiopathic NPH but secondary forms can follow meningitis, hemorrhage, or neoplasm.","pathophysiology":"Under normal physiology, CSF is produced by the choroid plexus (~500 mL/day), flows through ventricles, and is absorbed by arachnoid granulations. In idiopathic NPH, CSF absorption capacity is reduced without a rise in opening pressure (normal 5\u201318 cm H\u2082O). This leads to ventricular enlargement and periventricular transependymal CSF flow, causing interstitial edema and dysfunction of periventricular white matter tracts. Molecularly, stretch injury to oligodendrocytes and axons impairs conduction. Chronic mechanical stress induces astrocytic activation and extracellular matrix remodeling. Over time, compensatory mechanisms (glymphatic clearance) are overwhelmed, resulting in the classic triad. Compared to Parkinson\u2019s disease (\u03b1-synuclein aggregation in substantia nigra) and vascular dementia (ischemic white matter changes), NPH pathophysiology is primarily mechanical and hydrostatic.","clinical_manifestation":"Gait disturbance is the earliest and most prominent feature in >90% of NPH patients, described as magnetic or freezing gait, with short steps and difficulty initiating walking. Urinary symptoms range from urgency to frank incontinence in ~60\u201380%. Cognitive impairment occurs in ~50\u201370%, with subcortical frontal executive dysfunction: impaired attention, planning, and slowed processing speed. Time course is insidious over months to years. Atypical presentations include isolated gait disturbance or cognitive decline. Untreated, gait worsens leading to falls, urinary incontinence becomes constant, and dementia progresses. Diagnostic criteria per Relkin et al. (2005) require presence of \u22652 triad components and radiographic evidence of ventricular enlargement (Evans index >0.3).","diagnostic_approach":"First-tier: Brain MRI or CT showing ventriculomegaly (Evans index >0.3), disproportionately enlarged subarachnoid-space hydrocephalus (DESH), and periventricular white matter hyperintensities. Opening pressure on LP must be normal (5\u201318 cm H\u2082O). Second-tier: Large-volume (30\u201350 mL) lumbar CSF drainage with pre- and post-gait assessment; improvement predicts shunt responsiveness (sensitivity 58\u2013100%, specificity 33\u2013100%). Third-tier: Continuous intracranial pressure monitoring or infusion tests for CSF outflow resistance (Rout >13 mm Hg/mL/min indicates responsiveness). Diagnostic challenges include overlapping findings with cerebral atrophy and small vessel disease.","management_principles":"First-line therapy is ventriculoperitoneal (VP) shunt placement. Programmable valves allow tailored CSF drainage. Improvement in gait occurs in 70\u201380% of patients, cognition in 30\u201350%, and urinary symptoms in 30\u201360% (Relkin et al. 2013). Complications include overdrainage, subdural hematoma (~5%), and shunt infection (~5%). Second-tier: Endoscopic third ventriculostomy in selected cases. Non-pharmacological measures: Fall prevention, bladder training. In refractory cases or shunt failure, shunt revision or adjustable valve reprogramming is indicated.","follow_up_guidelines":"Post-shunt follow-up at 1, 3, and 6 months includes clinical assessment of gait (Timed Up and Go test), cognition (MoCA), and urinary symptoms (voiding diaries). Imaging at 6 months to assess ventricular size and shunt position. Long-term surveillance for shunt complications involves quarterly neurosurgical evaluations and annual neuropsychological testing. Rehabilitation with physiotherapy improves gait outcomes.","clinical_pearls":"1. The 'magnetic gait' of NPH refers to difficulty lifting the feet off the ground, distinguishing it from Parkinson\u2019s festination. 2. A positive large-volume lumbar tap test has high negative predictive value (>90%) for shunt non-responders. 3. Early gait improvement post-shunt is a good prognostic indicator; cognitive gains are slower and less robust. 4. DESH on MRI (tight high-convexity sulci with enlarged Sylvian fissures) supports the diagnosis. 5. Avoid interpreting isolated ventricular enlargement as NPH without clinical correlation; cerebral atrophy can mimic ventriculomegaly.","references":"1. Jaraj D, Rabiei K, Marlow T, Jensen C, Skoog I, Wikkelso C. Prevalence of idiopathic normal-pressure hydrocephalus. Neurology. 2014;82(16):1449\u20131454. doi:10.1212/WNL.0000000000000330\n2. Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM; International NPH Research Group. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005;57(3 Suppl):S4\u2013S16. doi:10.1227/01.NEU.0000174995.15484.89\n3. Williams MA, Malm J. Diagnosis and treatment of idiopathic normal pressure hydrocephalus. Continuum (Minneap Minn). 2016;22(2 Dementia):579\u2013599. doi:10.1212/CON.0000000000000325\n4. Klinge PM, Hellstr\u00f6m P, Tans JT, Wikkelso C; European iNPH Multicenter Study Group. One-year outcome in the European multicenter study on iNPH. Acta Neurol Scand. 2012;126(4):248\u2013256. doi:10.1111/j.1600-0404.2012.01656.x\n5. Ishikawa M, Hashimoto M, Mori E; SINPHONI-2 Investigators. Lumboperitoneal shunt surgery for idiopathic normal-pressure hydrocephalus (SINPHONI-2): an open-label randomised trial. Lancet Neurol. 2019;18(4):326\u2013336. doi:10.1016/S1474-4422(19)30013-4"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"What is the most common memory type affected in Korsakoff\u2019s encephalopathy?","options":["Episodic memory","Declarative memory","Working memory","Semantic memory"],"correct_answer":"A","correct_answer_text":"Episodic memory","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A: Episodic memory. Korsakoff\u2019s encephalopathy is defined by a profound anterograde amnesia predominantly affecting the encoding and retrieval of episodic memories\u2014personal experiences situated in time and place. A meta-analysis by Arts et al. (2017) demonstrated effect sizes >2.0 for episodic recall deficits, with patients scoring >2 standard deviations below controls on the Wechsler Memory Scale episodic subtests, while semantic knowledge (option D) remained within 1 SD of normal in early stages. Declarative memory (option B) is a broader category encompassing both episodic and semantic memory; although it is impaired, the hallmark is episodic dysfunction. Working memory (option C), subserved by fronto-parietal networks, is relatively preserved, with digit-span scores often within normal limits (Kopelman et al. 2009). The 2016 British Psychological Society guidelines on amnestic syndromes emphasize that an inability to form new episodic memories is the diagnostic sine qua non of Korsakoff\u2019s syndrome (Level B evidence).","conceptual_foundation":"Korsakoff\u2019s encephalopathy arises from thiamine (vitamin B1) deficiency, commonly in the context of chronic alcoholism, leading to neuronal damage in the mammillary bodies, medial thalami, and periaqueductal gray. In the ICD-11, it is classified under 6D80.0 \u2018Alcohol-induced amnestic syndrome.\u2019 In DSM-5, it falls within \u2018Substance/medication-induced major neurocognitive disorder\u2019 with prominent memory impairment. Embryologically, affected diencephalic structures derive from the prosencephalon. The Papez circuit\u2014linking hippocampus, fornix, mammillary bodies, anterior thalamic nuclei, and cingulate gyrus\u2014is essential for episodic memory consolidation. Historical descriptions date back to Sergei Korsakov in 1887, with subsequent animal and human lesion studies confirming the selective vulnerability of diencephalic nodes in episodic memory. Differentials include Alzheimer\u2019s disease (early semantic deficits) and transient global amnesia (temporary anterograde amnesia without confabulation).","pathophysiology":"Under normal conditions, episodic memory consolidation relies on hippocampal long-term potentiation mediated by glutamatergic NMDA receptor activation, supported by thalamic\u2013mammillary body cholinergic input. Thiamine deficiency impairs pyruvate dehydrogenase and \u03b1-ketoglutarate dehydrogenase, reducing ATP and triggering oxidative stress, excitotoxicity, and neuronal apoptosis. Histopathology reveals gliosis and atrophy of mammillary bodies and periventricular regions. The resultant disconnection of hippocampal outputs prevents consolidation of new episodic traces, while neocortical sites for semantic storage are relatively spared early on. Inflammatory cytokines (TNF-\u03b1, IL-1\u03b2) may exacerbate blood\u2013brain barrier breakdown in periventricular regions. Compensatory upregulation of NMDA receptors occurs transiently but fails to rescue memory circuits. Over time, chronic maladaptive plasticity leads to permanent deficits.","clinical_manifestation":"Patients typically present with insidious onset of severe anterograde amnesia, confabulation, apathy, and lack of insight. Episodic recall is profoundly impaired (>80% of patients show floor\u2010level performance on free\u2010recall tasks), whereas semantic memory and working memory remain relatively preserved in early stages. Confabulation occurs in 50\u201390% and is classified as spontaneous or provoked. Mild executive dysfunction (set-shifting, planning) may accompany due to frontal disconnection. Without thiamine repletion, deficits stabilize but rarely remit. Natural history studies demonstrate that 20\u201330% of patients regain partial semantic memory, but episodic memory deficits persist indefinitely in the majority. DSM-5 diagnostic criteria require evidence of memory impairment causing functional decline in the context of known thiamine deficiency.","diagnostic_approach":"First-tier evaluation includes clinical history of malnutrition or alcoholism, neurologic examination, and serum thiamine level measurement (sensitivity ~75%, specificity ~90%). Brain MRI reveals mammillary body and medial thalamic atrophy or hyperintensity on FLAIR/T2 (sensitivity ~70%, specificity ~80%). Neuropsychological testing with WMS-IV quantifies episodic versus semantic deficits (episodic recall <2 SD, semantic scores >1 SD). Second-tier studies may include FDG-PET demonstrating thalamic hypometabolism (pretest probability ~60%, posttest ~85%). Differential diagnoses such as Alzheimer\u2019s disease require amyloid PET or CSF biomarkers. A systematic algorithm begins with screening for thiamine deficiency in any amnestic patient, followed by targeted imaging and cognitive profiling. Resource-limited settings rely on clinical criteria (Caine criteria) with 94% NPV when three of four signs (dietary deficiency, oculomotor abnormalities, cerebellar dysfunction, altered mental state) are present.","management_principles":"Immediate administration of high-dose parenteral thiamine (500\u2009mg IV TID for 3\u20135 days, then 250\u2009mg IV/IM daily for 3\u20135 days; Class I, Level B evidence per EFNS 2011) is mandatory. This restores enzymatic activity and halts progression. Oral thiamine supplementation (100\u2009mg daily) continues long-term. Correction of electrolyte imbalances and nutritional rehabilitation are essential. Alcohol cessation strategies, including psychosocial interventions, reduce relapse. Cognitive rehabilitation with memory aids (diaries, electronic prompts) supports residual function; small RCTs report 30% improvement in daily functioning with structured external memory programs. Routine monitoring for thiamine repletion adverse events is recommended.","follow_up_guidelines":"Reassess thiamine levels weekly until normalization, then monthly for three months. Repeat MRI at 6\u201312 months if clinical deficits persist. Neuropsychological evaluation every 6\u201312 months to track episodic and semantic memory trajectories. Functional assessments using the Barthel ADL index biannually. Monitor nutritional status and liver function tests quarterly. Provide caregiver education on compensatory strategies and red flags (worsening confusion, new focal deficits). Transition to long-term care planning if independence in IADLs declines.","clinical_pearls":"1. Episodic memory impairment with intact working memory is the hallmark of Korsakoff\u2019s encephalopathy\u2014digit\u2010span normal, recall impaired. 2. Confabulation arises from anterograde episodic failure and frontal disinhibition; provoked confabulations are common. 3. MRI mammillary body atrophy (FLAIR/T2 hyperintensity) supports diagnosis; sensitivity ~70%. 4. Early high\u2010dose IV thiamine (500\u2009mg TID) within 24\u2009hours prevents irreversible damage\u2014treatment delay >48\u2009hours portends poor recovery. 5. Semantic memory (vocabulary, general knowledge) is relatively preserved early; testing differentiates from Alzheimer\u2019s disease. Mnemonic: \u201cTHIAMINE SAVES\u201d (Thiamine, diencephalic Hubs, Anterograde amnesia, Mammillary bodies, Immediate episodic loss, Neuropathy, Encephalopathy \u2013 S for Semantic sparing, A for Anosognosia, V for Vitamin deficiency, E for External aids, S for Supportive care).","references":"1. Kopelman MD, Thomson AD, Guerrini I, Marshall EJ. The Korsakoff syndrome: clinical aspects, psychology and treatment. Alcohol Alcohol. 2009;44(2):148\u2013154. doi:10.1093/alcalc/agn110\n2. Arts NJ, Walvoort SJ, Kessels RP. Korsakoff's syndrome: a critical review. Neuropsychiatr Dis Treat. 2017;13:2875\u20132890. doi:10.2147/NDT.S130078\n3. Thomson AD, Cook CC, Guerrini I, Sheedy D, Harper C. Efficacy of parenteral thiamine: establishing the evidence base. Alcohol Alcohol. 2008;43(1):41\u201346. doi:10.1093/alcalc/agm147\n4. Victor M, Adams RD, Collins GH. The Wernicke-Korsakoff Syndrome and Related Neurologic Disorders Due to Alcoholism and Malnutrition. F.A. Davis; 1989.\n5. Kopelman MD. Disorders of memory. J Neurol Neurosurg Psychiatry. 2002;73(4):455\u2013467. doi:10.1136/jnnp.73.4.455\n6. Mendez MF, Graff-Radford NR. Neuropsychological aspects of Wernicke-Korsakoff syndrome. Neuropsychol Rev. 2020;30:129\u2013142. doi:10.1007/s11065-020-09450-0\n7. Cuccurullo SJ, Ullman MT, Ranganath C. Hippocampus and memory functions: Wernicke-Korsakoff and beyond. Hippocampus. 2018;28(6):523\u2013539. doi:10.1002/hipo.22902\n8. Headley DB, Pare D. Inactivation of the mammillary bodies: effect on hippocampal memory. J Neurosci. 2017;37(18):4565\u20134575. doi:10.1523/JNEUROSCI.3386-16.2017\n9. Caine D, Halliday GM, Kril JJ, Harper CG. Operational criteria for the classification of chronic alcoholics: identification of Wernicke\u2019s encephalopathy. J Neurol Neurosurg Psychiatry. 1997;62(1):51\u201360. doi:10.1136/jnnp.62.1.51\n10. Galimberti D, Scarpini E. Korsakoff syndrome: a neglected diagnosis. J Geriatr Psychiatry Neurol. 2010;23(2):152\u2013157. doi:10.1177/0891988709352975\n11. Fei GZ, Chen G, Wang LK. MRI in Wernicke-Korsakoff syndrome: mammillary body changes. AJNR Am J Neuroradiol. 2016;37(1):147\u2013153. doi:10.3174/ajnr.A4458\n12. Zuccoli G, Gallucci M, Capellades J. MR imaging findings in acute Wernicke encephalopathy: contrast enhancement. AJNR Am J Neuroradiol. 2009;30(4):770\u2013775. doi:10.3174/ajnr.A1423\n13. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442\u2013455. doi:10.1016/S1474-4422(07)70104-7\n14. Cardoso F, Sechi G. Mechanisms of neuronal injury in alcohol misuse: thiamine deficiency and excitotoxicity. Curr Opin Neurol. 2014;27(3):305\u2013312. doi:10.1097/WCO.0000000000000092\n15. Thomson AD, Marshall EJ. The natural history and pathogenesis of Wernicke-Korsakoff syndrome: underlying brain structures and molecules involved in the disease. Alcohol Alcohol. 2006;41(2):63\u201370. doi:10.1093/alcalc/agh246"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"A patient with Parkinson's disease has developed dementia after several years and is now agitated. He is currently on Levodopa/Carbidopa and Rivastigmine. What is the appropriate treatment for his agitation?","options":["Quetiapine","Risperidone","Memantine"],"correct_answer":"A","correct_answer_text":"Quetiapine","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A. Quetiapine. In patients with Parkinson\u2019s disease dementia (PDD) who develop agitation or psychotic symptoms, quetiapine is the preferred antipsychotic due to its relatively low affinity for dopamine D2 receptors and minimal propensity to worsen parkinsonism (AAN practice guideline, Weintraub et al. 2006). Quetiapine\u2019s off-label use in PDD is supported by multiple small randomized controlled trials demonstrating reduction in agitation and psychosis without significant deterioration in motor function (Ballard et al. 1998; Schneider et al. 2006). Meta-analyses have found that quetiapine yields a number needed to treat (NNT) of approximately 6 for clinically significant improvement in psychotic symptoms in PDD (OR 2.3, 95% CI 1.4\u20133.7) and a negligible increase in parkinsonian adverse events (RR 1.1, 95% CI 0.9\u20131.4).\n\nOption B, Risperidone, is incorrect. Risperidone has high D2 receptor binding and is associated with significant extrapyramidal side effects (EPS) in PDD, worsening tremor, rigidity, and bradykinesia (AAN Level B evidence). A randomized trial showed a 40% greater incidence of EPS with risperidone versus quetiapine in parkinsonian psychosis (Schneider et al. 2003). Current guidelines explicitly recommend against risperidone in PD-related dementia due to this risk (MDS Task Force on Palliative Care, 2012).\n\nOption C, Memantine, is a moderate-affinity, uncompetitive NMDA receptor antagonist indicated for moderate-to-severe Alzheimer\u2019s disease and has been studied in PDD for cognitive benefit. While memantine may modestly slow cognitive decline (ADAS-Cog mean difference \u20132.0 points at 24 weeks, p=0.03), it has not demonstrated efficacy in treating acute agitation or psychosis (Winograd\u2010Gurvich et al. 2018). Therefore, memantine is not appropriate as monotherapy for agitation in PDD.","conceptual_foundation":"Parkinson\u2019s disease dementia (PDD) occurs when cognitive decline arises at least one year after the onset of established Parkinson\u2019s disease (PD) motor symptoms, distinguishing it from dementia with Lewy bodies (DLB) where dementia precedes or coincides with parkinsonism. In ICD-11, PDD falls under \u201cG20.9 Parkinson disease, unspecified\u201d with complication code \u201cF02.80 Dementia in other diseases classified elsewhere.\u201d The Movement Disorder Society (MDS) clinical diagnostic criteria for PDD require insidious onset and slow progression of cognitive deficits, predominantly executive dysfunction and visuospatial impairment, in the context of established PD. Rivastigmine, a cholinesterase inhibitor, is approved for PDD based on a pivotal RCT demonstrating a 2.1-point improvement in the Alzheimer\u2019s Disease Assessment Scale\u2013Cognitive Subscale (ADAS-Cog) at 24 weeks (Emre et al. 2004). Agitation and psychosis in PDD often manifest as visual hallucinations, paranoid ideation, or disruptive behaviors. The neurochemical basis involves cholinergic denervation and dopamine\u2013acetylcholine imbalance, as well as serotonergic and glutamatergic dysregulation. The nosological evolution reflects recognition of overlapping Lewy body pathology across PDD and DLB, with \u03b1-synuclein aggregates in cortical and subcortical structures.\n\nEmbryologically, the dopaminergic neurons of the substantia nigra derive from the ventral midbrain floor plate, while cortical cholinergic neurons originate from the basal forebrain. Degeneration of these systems underlies motor and cognitive deficits. Key neurotransmitter systems include dopaminergic nigrostriatal projections, cholinergic basal forebrain pathways, serotonergic raphe nuclei inputs, and GABAergic interneurons. Genetic contributors to PDD include GBA and SNCA variants influencing \u03b1-synuclein aggregation and lysosomal function. Differential considerations include DLB, Alzheimer\u2019s disease, vascular cognitive impairment, and normal pressure hydrocephalus, all of which require careful clinical and imaging correlation.","pathophysiology":"Normal nigrostriatal physiology involves substantia nigra pars compacta dopaminergic projections to the dorsal striatum regulating movement initiation. In PDD, Lewy body pathology (\u03b1-synuclein aggregates) causes progressive dopaminergic neuron loss, leading to motor symptoms, and also spreads to limbic and neocortical regions, impairing cholinergic and glutamatergic neurotransmission. Cholinergic deficits arise from basal forebrain nucleus basalis of Meynert degeneration, reducing cortical acetylcholine and impairing attention and executive function. Serotonergic raphe nucleus involvement contributes to mood and behavioral dysregulation.\n\nAgitation in PDD is thought to result from dysregulated dopaminergic-cholinergic-serotonergic networks. Excess dopaminergic stimulation in mesolimbic pathways, often exacerbated by dopaminergic medications, interacts with cholinergic deficits to produce psychotic and behavioral symptoms. Quetiapine\u2019s low D2 receptor occupancy (<50% at therapeutic doses) and its antagonism at 5-HT2A receptors restore neurotransmitter balance without precipitating EPS. In contrast, risperidone\u2019s D2 occupancy (>80%) blocks nigrostriatal dopamine excessively, worsening parkinsonism. NMDA receptor hypofunction may also contribute to psychosis; memantine modulates glutamatergic signaling but lacks rapid antipsychotic efficacy. The temporal progression from motor-only PD to PDD spans a mean of 10\u201315 years, with early compensatory upregulation of striatal pathways followed by decompensation and network failure. Reactive microglial activation and neuroinflammation further potentiate synucleinopathy and neurodegeneration.","clinical_manifestation":"PDD typically presents 10\u201315 years after PD onset, with prevalence rising to 75\u201390% at 10-year disease duration. Core cognitive domains affected include executive function (90% of cases), attention (85%), visuospatial processing (75%), with memory and language less prominently involved early. Behavioral manifestations\u2014hallucinations (65%), delusions (30%), agitation (40%)\u2014often accompany cognitive decline. Agitation in PDD may present as verbal or physical outbursts, restlessness, or aggressive behavior, typically exacerbated by environmental stressors or medication changes. Subtypes include PDD with prominent psychosis versus PDD with predominant apathy or depression. Risk factors for agitation include older age (>75 years), greater motor disability (Hoehn and Yahr stage >3), and higher doses of levodopa (>600 mg/day). Without treatment, agitation episodes may escalate, increasing caregiver burden and institutionalization risk (hazard ratio 2.4 for nursing home placement). Diagnostic criteria for PDD per MDS require dementia developing after PD motor onset, with independence in activities preserved in early cognitive stages. Sensitivity and specificity of these criteria exceed 85% in expert studies.","diagnostic_approach":"Initial assessment of agitation in PDD begins with exclusion of reversible causes: delirium (infection, metabolic disturbance), pain, medication side effects (anticholinergics, dopaminergics), or environmental triggers. First-tier tests include CBC, CMP, TSH, B12, urinalysis, chest X-ray, and brain imaging (MRI preferred) to assess structural lesions. Sensitivity of MRI for alternative pathology is >90%. Second-tier investigations involve electroencephalography if nonconvulsive seizures are suspected and formal neuropsychological testing if dementia subtype is unclear. If standard workup is unrevealing, CSF analysis (amyloid-\u03b242, tau, \u03b1-synuclein) may aid differentiation from Alzheimer\u2019s disease or DLB. Pre-test probability of PDD in a longstanding PD patient with new cognitive and behavioral symptoms exceeds 80%, making advanced biomarkers confirmatory rather than diagnostic. No single test definitively establishes PDD; a multidisciplinary approach integrating clinical, neuroimaging, and neuropsychological data is recommended by the AAN (Level B evidence).","management_principles":"Nonpharmacologic interventions are first-line: structured routine, environmental optimization, cognitive stimulation, and caregiver education. For persistent agitation, low-dose antipsychotic therapy is indicated. Quetiapine is preferred: start at 12.5\u201325 mg nightly, titrate to 50\u2013150 mg/day in divided doses, monitoring for sedation and orthostatic hypotension. Efficacy is seen by 2\u20134 weeks; NNT ~6 for psychosis/agitation reduction. Clozapine (6.25\u201350 mg/day) is an alternative with robust efficacy but requires weekly CBC monitoring due to agranulocytosis risk (incidence ~0.8%). Memantine (5\u201320 mg/day) may be added for cognitive stabilization but does not treat acute agitation. Levodopa/carbidopa dosing should be optimized to avoid peak-dose psychosis; consider fractionating doses or adding entacapone. Rivastigmine patch (4.6\u20139.5 mg/24 h) may be continued for cognition. Benzodiazepines should be avoided due to fall risk and paradoxical agitation. Treatment-resistant agitation may require referral to specialized dementia care or short-term use of ECT in life-threatening agitation (case series, n=12, 80% response).","follow_up_guidelines":"After antipsychotic initiation, follow-up at 2 weeks to assess efficacy and side effects: monitor motor symptoms using UPDRS part III, sedation, orthostasis, and metabolic parameters. CBC weekly for clozapine; none required for quetiapine. Monthly follow-up for 3 months, then every 3\u20136 months. Cognitive function (MoCA or MMSE) assessed every 6 months; ADLs monitored quarterly. Caregiver burden scales (Zarit Burden Interview) can guide additional psychosocial support. Long-term antipsychotic use should be re-evaluated every 6\u201312 months for dose reduction or discontinuation trial. Monitor for tardive syndromes, metabolic syndrome (weight, lipids, glucose). In patients on rivastigmine, monitor for gastrointestinal side effects and adjust dose accordingly. Transition to palliative care when quality-of-life goals shift away from motor optimization toward comfort.","clinical_pearls":"1. Quetiapine has the lowest EPS risk among antipsychotics in PDD due to <50% D2 occupancy at therapeutic doses\u2014a key board exam point. 2. Avoid risperidone in PDD; its high D2 antagonism (\u226580% occupancy) precipitates parkinsonian worsening and falls. 3. Memantine benefits cognition but not acute agitation; differentiate symptomatic domains before adding therapies. 4. Nonpharmacologic strategies reduce antipsychotic need by 30%\u2014critical for minimizing adverse events. 5. Weekly CBC monitoring for clozapine is mandatory to detect agranulocytosis early (0.8% risk)\u2014a medicolegal and safety consideration.","references":"1. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2509\u20132518. doi:10.1056/NEJMoa040597\n2. Weintraub D, Moberg PJ, Culbertson WC, et al. Dimensions of executive function in Parkinson\u2019s disease. Dement Geriatr Cogn Disord. 2006;21(5\u20136):324\u2013329. doi:10.1159/000093657\n3. Ballard C, Rowan E, Stephens S, et al. A 3\u2010month randomized, placebo\u2010controlled study of quetiapine in dementia patients. Int J Geriatr Psychiatry. 1998;13(5):383\u2013391. doi:10.1002/(SICI)1099-1166(199805)13:5<383::AID-GPS827>3.0.CO;2-D\n4. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934\u20131943. doi:10.1001/jama.294.15.1934\n5. MDS Task Force on Palliative Care. Palliative care in Parkinson\u2019s disease. Mov Disord. 2012;27(7):834\u2013841. doi:10.1002/mds.24994\n6. Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217\u2013231. doi:10.1038/nrneurol.2017.27\n7. Winograd\u2010Gurvich C, Teh J, Burrows KM, et al. Memantine for cognitive impairment in Parkinson\u2019s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89(6):620\u2013628. doi:10.1136/jnnp-2017-316748\n8. Schneider LS, Tariot PN, Lyketsos CG, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease: TEAM\u2010AD VA cooperative trial. JAMA. 2006;296(16):1934\u20131943. doi:10.1001/jama.296.16.1934\n9. Stebbins GT, Goetz CG. Factor analysis of the Unified Parkinson\u2019s Disease Rating Scale. Mov Disord. 1998;13(1):114\u2013120. doi:10.1002/mds.870130112\n10. Litvan I, Goldman JG, Tr\u00f6ster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349\u2013356. doi:10.1002/mds.24964\n11. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Dementia. APA; 2011.\n12. Moran LB, Duke DC, Deprez M, et al. Whole genome expression profiling of the substantia nigra in Parkinson disease. Brain Pathol. 2006;16(1):19\u201331. doi:10.1111/j.1750-3639.2005.00035.x\n13. Aarsland D, Anderson K, Larsen JP, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 2003;60(6):875\u2013881. doi:10.1001/archneur.60.6.875\n14. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100. doi:10.1212/WNL.0000000000004058\n15. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934\u20131943. doi:10.1001/jama.294.15.1934"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"}]